Abstract
Breakthroughs in understanding the pathogenesis of renal cell carcinoma have led to recent therapeutic advances in this disease. However, the US FDA approval of sunitinib and sorafenib (and soon temsirolimus) after successful Phase III trials must also be attributed to the work of clinical investigators over the past decade defining the outcomes and major prognostic factors in patients with advanced renal cell carcinoma. Those past studies have been critical in providing a context for the interpretation of future trials with novel agents, optimizing patient selection for specific therapeutic approaches and identifying appropriate variables for patient stratification on randomized trials. This review will focus on studies that define the outcome and prognosis in advanced renal cell carcinoma.
| Original language | English |
|---|---|
| Pages (from-to) | 839-845 |
| Number of pages | 7 |
| Journal | Expert Review of Anticancer Therapy |
| Volume | 7 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 2007 |
| Externally published | Yes |
Keywords
- Metastatic
- Prognosis
- Prognostic models
- Renal neoplasm